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OBJECTIVE: To determine the molecules involved in extracellular matrix remodeling and to identify and quantify
heparanase isoforms present in herniated and degenerative discs.
INTRODUCTION: Heparanase is an endo-beta-glucuronidase that specifically acts upon the heparan sulfate chains of
proteoglycans. However, heparanase expression in degenerative intervertebral discs has not yet been evaluated.
Notably, previous studies demonstrated a correlation between changes in the heparan sulfate proteoglycan pattern
and the degenerative process associated with intervertebral discs.
METHODS: Twenty-nine samples of intervertebral degenerative discs, 23 samples of herniated discs and 12 samples
of non-degenerative discs were analyzed. The expression of both heparanase isoforms (heparanase-1 and
heparanase-2) was evaluated using immunohistochemistry and real-time RT-PCR analysis.
RESULTS: Heparanase-1 and heparanase-2 expression levels were significantly higher in the herniated and
degenerative discs in comparison to the control tissues, suggesting a possible role of these proteins in the
intervertebral degenerative process.
CONCLUSION: The overexpression of heparanase isoforms in the degenerative intervertebral discs and the herniated
discs suggests a potential role of both proteins in the mediation of inflammatory processes and in extracellular
matrix remodeling. The heparanase-2 isoform may be involved in normal metabolic processes, as evidenced by its
higher expression in the control intervertebral discs relative to the expression of heparanase-1.
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INTRODUCTION
It has been suggested that the majority of back pain is
caused by intervertebral disc degeneration (IVD), which is a
condition that can lead to spinal stenosis, radiculopathy,
disc herniation, and age-related histological alterations.1,2
IVD describes a complex set of biochemical changes that
can progress with age and is associated with increased
cigarette smoking, obesity, diabetes and other heredity
factors.3–6 However, the biological and pathological pro-
cesses that occur during disc degeneration remain poorly
understood. Therefore, existing medical and surgical treat-
ments are limited and provide unpredictable outcomes.7
During aging, small leucine-rich proteoglycans located in
the inner and outer annulus fibrosus (AF) and nucleus
pulposus (NP) are structurally modified. The concentrations
of small proteoglycans such as biglycan have been shown to
increase in all regions of the disc (the AF and NP regions),
whereas the levels of decorin and collagen content tend to
decrease.8,9-11
Notably, heparan sulfate (HS) is present within the tissue
microenvironment and functions as a major constituent of
the HS proteoglycans (HSPG) and as free HS chains that are
involved in angiogenesis and osteogenesis.12
Heparanase-1 (HPA1), a mammalian endo-beta-glucur-
onidase, promotes the cleavage of HS and generates
oligosaccharides that are able to activate angiogenesis and
the activity of growth factors, cytokines and chemo-
kines.13,14
Most studies investigating HPA1 have focused on its
regulated expression at different stages of cancer progres-
sion. In bone tissue, HPA1 overexpression creates a complex
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phenotype that typically results in osteogenesis and
increased bone mass.15 Gomes et al.16 provided evidence
of a dramatic loss of HS in the chondro-osseous junction
during endochondral bone formation processes, suggesting
that HS inhibits osteogenesis. Notably, heparanase-2
(HPA2), an isoform of heparanase, does not exhibit
enzymatic activity and its function remains unclear.17,18
The main objective of our study was to evaluate the
expression of both heparanase isoforms (HPA1 and HPA2)
in IVD by comparing patient samples of herniated discs with
samples of non-degenerative discs (control group) to better
understand the role of HPA1 and HPA2 in IVD and to identify
any corresponding extracellular matrix (ECM) alterations.
METHODS
Patients and tissues
The present study analyzed 29 samples of intervertebral
degenerative discs, 23 samples of herniated discs and 12
samples of non-degenerative discs; the latter samples were
obtained from surgeries performed on patients character-
ized with an accidental fracture. It is important to note that
patients from the control group did not report any previous
lumbar pain. The samples were collected between February
2008 and January 2009. The intervertebral disc specimen
samples were collected via resection of the annulus fibrosis
and nucleus pulposus of 53 patients (aged 18 to 43 years)
and 12 healthy donors (aged 21 to 35 years). This study
conformed to the regulations of the Human Ethics Research
Committee at Faculdade de Medicina do ABC number 262/
2008.
Histological and clinical features
All patients were subjected to magnetic resonance
imaging (MRI), and the degenerative disc samples were
characterized using the Pfirrmann grading system.19 T2-
weighted sagittal images were used to determine the grade
of the disc degeneration (grade 1: normal; grade 5: advanced
degeneration). Only the specimens classified according to
the MRI evaluation as Pfirrmann grades 2, 3 and 4 were
further analyzed. Lumbar intervertebral disc tissues (AF or
NP) were collected during the surgical procedure from
patients with degenerative lumbar discs (patient group) or
from individuals who, because of an accident, fractured
their intervertebral disc, which thereafter required surgical
removal. Histological parameters (including cellularity,
inflammatory infiltrates, neovascularization, cell death,
mucous degeneration, calcification, granular changes and
clefts or microfractures) were analyzed at two regions of the
disc, the NP and AF regions, using a semi-quantitative
assessment performed using ten high-power fields (400X)
((0) = absent; (+) = rarely present; (++) = present in inter-
mediate amounts; and (+++) = abundantly present).
In the present study, the samples from the degenerative
disc group and the herniated disc group were classified as
Pfirrmann grades II, III and IV, whereas the discs from the
control group were classified only as Pfirrmann grade I. We
excluded discs with a Pfirrmann grade I.
Immunohistochemical staining
Representative lumbar intervertebral degenerative disc
regions were chosen based on the results of a hematoxylin-
eosin staining study of the corresponding tissue sec-
tions. Three-micrometer-thick sections of formalin-fixed
paraffin-embedded tissues were deparaffinized and rehy-
drated. The primary heparanase isoform antibodies HPA1 C-
20 and HPA2 C-17 (Santa Cruz, Biotechnology, CA, USA)
were diluted 15100 and incubated overnight. A universal
secondary biotinylated antibody (LSABH, DakoCytomationH,
Glostrup, Denmark) was applied for 30 minutes, and the
slides were subsequently incubated with a peroxidase-
labeled streptavidin complex (LSABH, DakoCytomation,
Glostrup, Denmark) for an additional 30 minutes. The
sections were developed using 3,39-diaminobenzidine as
the chromogen for one minute and were subsequently
counterstained with hematoxylin.
Digital quantification
The slides were analyzed using a TS100 Nikon EclipseH
light microscope to identify the areas that best represented
the immunostaining of HPA1 and HPA2 (hot spots). In each
case, quantification of the degree of immunostaining was
performed using a digital computer-assisted image analysis
method.20 Photomicrographs (6406480 pixels) were
obtained from non-coincident consecutive fields for each
case at a magnification of 400X using a 4300 Nikon CoolpixH
digital camera adjusted to the same parameters. The
resulting images were analyzed using the image processing
and analysis system ImageLabH (Softium Informa´ticaH, Sa˜o
Paulo, Brazil) adjusted to the micrometer scale (mm). The
index of the positive percentage of labeled cells (IP), the
index of the immunostaining intensity expression (ItE) and
the index of expression (IE) were obtained as described by
Matos.20
RNA extraction and cDNA synthesis
The total RNA was extracted from the lumbar disc tissue
resections using an RNAspin Mini Kit (GE Healthcare,
Germany) according to the manufacturer’s instructions.
RNA quantification was performed using an Agilent 2100
Bioanalyzer with an RNA 6000 Nano LabChip Kit (Agilent
Technologies, Palo Alto, CA, USA), and the RNA integrity
was analyzed via agarose gel electrophoresis to identify the
28S and 18S ribosomal rRNA. The first-strand cDNA was
synthesized using 5 mg of total RNA, 500 ng of oligo (dT)
and Superscript III reverse transcriptase (Invitrogen,
Carlsbad, USA). The reaction was performed at 50 C˚ for
60 minutes followed by a 15-minute incubation period at
70 C˚.
Quantitative RT-PCR
Quantitative RT-PCR was performed using SYBR Green I
according to the manufacturer’s instructions (Applied
Biosystems, Foster City, CA, USA) in conjunction with
Rotor-Gene 6000 Series Software 1.7 (Corbett Research,
USA). The relative expression levels were measured using
an efficiency correction,21 which considers the differences in
primer-pair amplification efficiencies between the target
and reference genes and results in a more reliable estimation
of the ‘‘real expression ratio’’ than the 2DDCt method.22
Measurements of glyceraldehyde-3-phosphate dehydrogen-
ase (GAPDH) and the ribosomal protein RPL13a were
performed and served as controls. The DCT value describes
the difference between the CT value (cycle threshold) of the
target gene and that of the corresponding endogenous
reference gene (e.g., housekeeping gene): DCT = CT (target
gene) – CT (endogenous reference gene). The DDCT value
represents the difference between the average DCT value of
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the sample of interest and the average DCT value of the
reference sample. The PCR amplifications were performed
using the following primer sequences: HPA1 forward
primer: 5’-TGGCAAGAAGGTCTGGTTAGGAGA-3’; HPA1
reverse primer: 5’-GCAAAGGTGTCGGATAGCAAGGG-3’;
GAPDH forward primer: 5’-GGAGAAGGCTGGGGCTC-39;
HPA2 forward primer: 5’-CGCCTGTTAGACACACTCTC-
TGA-3’; HPA2 reverse primer: 5’-GTCACCACACCTTCAA-
GCCAA-3’; GAPDH reverse primer: 5’-GTCCTTCCACG-
ATACCAAAG-39; the ribosomal protein (RPL13a) forward
primer 5’-TTGAGGACCTCTGTGTATTTGTCAA-39; and the
RPL13a reverse primer 5’-CCTGGAGGAGAAGAGGAA-
AGAGA-39.
Statistical analysis
Statistical analysis was performed using the SPSS 17.0
program for Windows (SPSS, Chicago, IL). The parame-
tricity of variables was determined using the Kolmogorov-
Smirnov test. The Chi-square test and the t-test were used
for parametric analyses, whereas the Mann-Whitney and
Kruskal-Wallis tests were used for non-parametric analyses.
The level of statistical significance adopted for all analyses
was P,0.05.
RESULTS
The average age of patients in this study with lumbar disc
degeneration, the average age of patients with herniated
discs and the average age of controls was 33.4¡7.03,
34.1¡6.61 and 29.5¡6.26 years, respectively. There were
no statistically significant differences among these groups
with regard to the average age (P= 0.199, Kruskal-Wallis
test).
Of the 53 intervertebral lumbar discs that were resected
from patients and subsequently evaluated, there were 29
degenerative discs (54.7%) and 24 herniated discs (45.3%).
There were statistically significant differences between the
histological and clinical features observed for the herniated
and control discs, including cellularity, neovascularization,
mucous degeneration, calcification, granular changes, clefts
or microfracture formation, and the presence or absence of
lumbar disc herniation (Table 1). However, no statistically
significant differences were observed regarding inflamma-
tory infiltrates and cell death upon comparison of the
herniated disc group and the control group (Table 1).
Similarly, cellularity, mucous degeneration, calcification
processes, granular changes, clefts or microfracture forma-
tion were statistically different upon comparison of the
degenerative discs with the control discs (Table 2), whereas
no statistically significant differences were observed
between these two groups for the clinical features and
histological parameters including inflammatory infiltrates,
neovascularization and cell death (Table 2).
HPA1 and HPA2 were identified using immunohisto-
chemistry in the NP and AF regions of the control lumbar
intervertebral discs (Figure 1). As demonstrated in Figure 1,
the expression of both protein isoforms (HPA1 and HPA2)
was higher in the degenerative discs than in the control
discs.
Figures 1A and 1B demonstrate the negative immunor-
eactivity of HPA1 and HPA2, respectively. Although many
fibroblasts were observed in the control AF, no vessels were
observed. Moreover, evidence of neovascularization was
observed in Figure 1C (degenerative AF). Although there
was almost no HPA1 immunoreactivity observed in the
fibroblasts, intense labeling could be observed in the
extracellular matrix. Conversely, intense HPA2 immunor-
eactivity was observed in the inflammatory infiltrate of the
AF of the degenerative discs, whereas low levels of labeling
were observed in the extracellular matrix (Figure 1D).
A lack of immunoreactivity for HPA1 and HPA2 were
observed in the chondrocytes and the extracellular matrix of
the control NP (Figures 1E and 1F), respectively. Strong
positive immunoreactivities for HPA1 and HPA2 were
observed in the NP region of the degenerative lumbar discs
(Figures 1G and 1H, respectively), which was also char-
acterized by hypercellularity.
The expression index (IE) of HPA1 was significantly
higher in the herniated (76.78¡29.19 ou/mm2) and degen-
erative lumbar intervertebral discs (83.59¡33.20 ou/mm2)
when compared with the control intervertebral discs
(19.46¡5.23 ou/mm2, P,0.001, Mann-Whitney test,
Figure 2). Similarly, the expression of the HPA2 isoform
was significantly higher in the herniated (82.67¡29.72 ou/
mm2) and degenerative discs (81.37¡29.04 ou/mm2) when
compared with the control discs (28.25¡10.19 ou/mm2,
P,0.001, Mann-Whitney test).
Table 1 - Clinical features and histological parameters in
herniated and control discs.
Group
Herniated
(n= 23)
Control
(n = 12) P
Cellularity
(+) 4 (17.4) 0 (0.0) 0.042 *
(++) 14 (60.9) 12 (100.0)
(+++) 5 (21.7) 0 (0.0)
Inflammatory
infiltrates
0 17 (73.9) 12 (100.0) 0.151
(+) 4 (17.4) 0 (0.0)
(++) 2 (8.7) 0 (0.0)
Neovascularozation
0 13 (56.5) 12 (100.0) 0.026 *
(+) 6 (26.1) 0 (0.0)
(++) 4 (17.4) 0 (0.0)
Cell Death
(+) 3 (13.0) 0 (0.0) 0.251
(++) 12 (52.2) 5 (41.7)
(+++) 8 (34.8) 7 (58.3)
Mucous
degeneration
(+) 0 (0.0) 6 (50.0) ,0.001 *
(++) 12 (52.2) 5 (41.7)
(+++) 11 (47.8) 1 (8.3)
Calcification
0 11 (47.8) 11 (91.7) 0.035 *
(+) 7 (30.4) 1 (8.3)
(++) 5 (21.7) 0 (0.0)
Granular changes
0 5 (21.7) 3 (25.0) 0.027 *
(+) 7 (30.4) 9 (75.0)
(++) 8 (34.8) 0 (0.0)
(+++) 3 (13.0) 0 (0.0)
Clefts or
microfractures
0 4 (17.4) 0 (0.0) 0.034 *
(+) 7 (30.4) 0 (0.0)
(++) 10 (43.5) 9 (75.0)
(+++) 2 (8.7) 3 (25.0)
Percentage (%); * Statistical significance (Chi-square test).
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None of the clinical or histological parameters reported in
Tables 2 and 3 for the herniated discs (n = 24 patients) and
degenerative discs (n = 29 patients, data not shown) were
statistically different.
Although both IP and IE indices indicated higher
expression levels in the herniated and degenerative discs
in comparison to the control group, no statistically
significant differences were observed between the HPA1
and HPA2 immunoexpression intensity index (ItE) (data not
shown).
There was a higher expression of the HPA2 isoform
(28.25¡10.19 ou/mm2) than the HPA1 isoform
(19.46¡5.23 ou/mm2, P= 0.028, Mann-Whitney test) in the
control discs.
The expression of the heparanase isoforms was also
investigated using quantitative RT-PCR analysis. The HPA1
and HPA2 mRNAs were more highly expressed in the
herniated and degenerative intervertebral discs than in the
control intervertebral discs (Figure 3).
The quantitative RT-PCR analysis revealed significantly
higher HPA1 expression in the herniated interver-
tebral discs (1.73¡0.80) when compared with the control
intervertebral discs (0.16¡0.02, P,0.05, Student’s t-test,
Figure 3).
Similar results were obtained for the HPA2 qRT-PCR,
which indicated an increased expression of HPA2 in the
herniated discs in comparison to the control discs, with
values of 0.77¡0.12 and 0.27¡0.03, respectively (P,0.05,
Student’s t-test, Figure 3).
The HPA1 expression was significantly higher in the
degenerative discs (2.25¡0.70) than in the control group
(0.16¡0.02, P,0.05, Student’s t-test). In addition, these
results indicated that HPA2 was overexpressed in the
degenerative discs in comparison to the control discs, with
values of 8.62¡2.69 and 0.27¡0.03, respectively (P,0.001,
Student’s t-test, Figure 3).
The immunohistochemistry and qRT-PCR analyses con-
firmed that the HPA2 isoform was up-regulated by
approximately 60–70% in the control discs in comparison
to the HPA1 isoform and also that the herniated and
degenerative discs expressed significantly higher amounts
of both heparanase isoforms when compared with the
control discs (i.e., discs not affected by intervertebral
disease).
As shown in Figure 3, the quantitative RT-PCR demon-
strated a statistically significant difference in the expression
of HPA1 and HPA2 in the herniated and degenerative discs.
HPA1 and HPA2 mRNA levels were higher in the
degenerative discs.
DISCUSSION
The observation of different rates of lumbar disc
degeneration has suggested the existence of distinct
pathways of degenerative intervertebral disc disease.
One such pathway for disc degeneration involves an
inflammatory response associated with an injury or other
mode of mechanical stress, whereas aging represents a
normal progression of the degenerative process with
observable cellular and molecular changes in the ECM.23
It is important to note that the present study evaluated a
group of young individuals within a fairly finite age range,
which necessarily precludes the ability to draw conclu-
sions based on age-dependent and occupation-dependent
relationships.
This study demonstrates that the expression levels of both
heparanase isoforms (HPA1 and HPA2) are significantly
higher in degenerative intervertebral AF and NP tissues
when compared with control tissues, suggesting a possible
role of HPA1 and HPA2 in the pathophysiology of this
disease. It is important to note that the chondrocytes in the
degenerative NP discs studied herein were intensely
immunoreactive for both HPA1 and HPA2.
The histological analysis demonstrated a significant
increase in the neovascularization of the herniated discs in
comparison to the control discs. In addition, the immuno-
histochemical analysis of the AF region clearly demon-
strated that HPA2 was significantly overexpressed in the
inflammatory infiltrate, whereas the HPA1 immunoreaction
was more prominent in the extracellular matrix.
Moreover, it is known that structural changes to the
cartilage endplate reduce the nutrient supply, causing
continuous adaptive tissue changes that may stimulate
intervertebral degeneration and subsequent modifications
in the heparan sulfate proteoglycan distribution within the
basal membrane, not unlike what happens to perlecan.
Table 2 - Clinical features and histological parameters in
degenerative and control discs.
Group
Degenerative
(n = 29)
Control
(n = 12) P
Cellularity
(+) 10 (34.5) 0 (0.0) 0.004 *
(++) 13 (44.8) 12 (100.0)
(+++) 6 (20.7) 0 (0.0)
Inflammatory
infiltrates
0 21 (72.4) 12 (100.0) 0.128
(+) 7 (24.1) 0 (0.0)
(++) 1 (3.4) 0 (0.0)
Neovascularozation
0 19 (65.5) 12 (100.0) 0.065
(+) 6 (20.7) 0 (0.0)
(++) 4 (13.8) 0 (0.0)
Cell Death
(+) 3 (10.3) 0 (0.0) 0.131
(++) 18 (62.1) 5 (41.7)
(+++) 8 (27.6) 7 (58.3)
Mucous
degeneration
(+) 1 (3.4) 6 (50.0) 0.001 *
(++) 18 (62.1) 5 (41.7)
(+++) 10 (34.5) 1 (8.3)
Calcification
0 13 (44.8) 11 (91.7) 0.019 *
(+) 8 (27.6) 1 (8.3)
(++) 8 (27.6) 0 (0.0)
Granular changes
0 6 (20.7) 3 (25.0) 0.012 *
(+) 8 (27.6) 9 (75.0)
(++) 10 (34.5) 0 (0.0)
(+++) 5 (17.2) 0 (0.0)
Clefts or
microfractures
0 6 (20.7) 0 (0.0) ,0.0001 *
(+) 15 (51.7) 0 (0.0)
(++) 5 (17.2) 9 (75.0)
(+++) 3 (10.3) 3 (25.0)
Percentage (%); * Statistical significance (Chi-square test)
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Perlecan has the ability to sequester growth factors and
organize a diverse range of matrix components such as
those in the fetal spine.24,25 Such alterations of the heparan
sulfate proteoglycan structure in the extracellular matrix
may be explained by HPA1 overexpression, which degrades
heparan sulfate chains that primarily regulate the biological
function of proteoglycans.
It has been proposed that heparanase up-regulation may be
a novel therapeutic approach for the prevention and treatment
of osteoporosis because heparanase facilitates cartilage repla-
cement with bone at the chondro-osseous junction by
removing the heparan sulfate component of proteoglycans
(e.g. perlecan/HSPG2) that would otherwise prevent osteo-
genic cells from remodeling the hypertrophic cartilage.26
Figure 1 - Fibrous annulus and pulposus nucleus HPA1 and HPA2 immunohostochemistry. A, Fibrous annulus control disc HPA1 C20
Santa Cruz primary antibody; B, Fibrous annulus control disc HPA2 C17 primary antibody; C, Fibrous annulus degenerative disc HPA1
C20 Santa Cruz primary antibody; D, Fibrous annulus degenerative disc HPA2 C17 Santa Cruz primary antibody; E, Pulposus nucleus
control disc HPA1 C20 Santa Cruz primary antibody; F, Pulposus nucleus control disc HPA2 C17 Santa Cruz primary antibody; G, Pulposus
nucleus degenerative disc HPA1 C20 Santa Cruz primary antibody; H, Pulposus nucleus degenerative disc HPA2 C17 Santa Cruz primary
antibody. Magnification: 400X.
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It is also interesting to note that HPA2 was more highly
expressed than HPA1 in the control discs and in the
degenerated discs. This result suggests that HPA2 could be
involved in the normal metabolism of tissue because it has
no enzymatic activity. Therefore, in the control interverteb-
ral discs, extracellular remodeling would be uncommon,
and heparan sulfate degradation would be most likely
controlled by HPA1. However, in the degenerative and
herniated discs, HPA1 was overexpressed and may have
subsequently induced the formation of heparan sulfate
oligosaccharides. These specific oligosaccharides are known
to be involved with neovascularization, cell proliferation
and cell migration.14 Brown et al.26 demonstrated that
heparanase expression and activity influences chondrogenic
and osteogenic processes during endochondral bone forma-
tion. In addition, a recent study proposed that enhanced
osteoclastogenesis is promoted by high levels of heparanase
expressed in the cells, resulting in a dramatic increase in
bone reabsorption in vitro.27 Moreover, it has been found
that syndecan-1 mediates distal cross-talk with bone that
enhances osteoclastogenesis,27 and it has been reported that
high levels of HPA1 result in enhanced shedding of
syndecan-1.28
HPA1 and HPA2 overexpression was confirmed by the
analysis of protein and mRNA levels using immunohisto-
chemistry and quantitative RT-PCR, respectively. These
data validated once more that qRT-PCR represents a precise
methodology for differentiating between HPA1 and HPA2
expression in herniated, degenerative and control lumbar
intervertebral discs. These tissue analyses illustrated the
different ECM components present in these groups of discs,
which reflects an intense remodeling process in the
degenerative discs and a less intense display of alterations
in the herniated discs, in addition to a fairly stable
equilibrium state and minimal remodeling process in the
control discs.
The increased HPA1 expression in the herniated interver-
tebral discs may indirectly facilitate endothelial cell migration
and proliferation.29 In addition, the HPA2 isoform may be
involved with normal metabolic processes as suggested by the
overexpression observed in the control intervertebral discs
compared with the expression of the HPA1 isoform.
The results also led us to propose possible roles for both
heparanase isoforms in the calcification process of inter-
vertebral discs during herniation development.
For the first time, we report that degenerative interver-
tebral discs present a significant increase in the level of
heparanase expression, which suggests that heparan sulfate
proteoglycan alterations and extracellular matrix remodel-
ing changes are important events that may lead to a better
understanding of the molecular mechanisms of this disease.
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